DOV-216,303
DOV-216,303 (pronounced D-O-V two one six, three zero three) is a pharmaceutical drug that acts as a triple reuptake inhibitor, affecting the neurotransmitters serotonin, norepinephrine, and dopamine. It was developed by DOV Pharmaceutical, a biopharmaceutical company based in the United States.
Etymology
The name "DOV-216,303" is derived from the initials of the company that developed it, DOV Pharmaceutical. The numbers 216 and 303 do not have a known specific meaning and are likely part of a coding system used by the company to identify their various drug candidates.
Pharmacology
DOV-216,303 is a triple reuptake inhibitor, meaning it inhibits the reuptake of three neurotransmitters: serotonin, norepinephrine, and dopamine. This increases the amount of these neurotransmitters available in the brain, which can help to alleviate symptoms of certain mental health conditions, such as depression and anxiety disorders.
Clinical Trials
DOV-216,303 has undergone clinical trials to assess its safety and efficacy in treating depression and anxiety disorders. However, as of the current date, it has not been approved for use by the Food and Drug Administration (FDA) or any other regulatory authority.
Related Terms
- DOV Pharmaceutical
- Triple reuptake inhibitor
- Serotonin
- Norepinephrine
- Dopamine
- Clinical trials
- Depression
- Anxiety disorders
External links
- Medical encyclopedia article on DOV-216,303
- Wikipedia's article - DOV-216,303
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski